Sarafan ChEM-H
Showing 1-34 of 34 Results
-
Thomas J Cirino
Research Scientist, Animal Pharmacology, Innovative Medicines Accelerator (IMA)
BioIn Vivo Pharmacologist with expertise in CNS disorders including neurodegenerative disease, psychiatric disorders and pain.
-
Jean Dam
Research Scientist, Medicinal Chemistry, Innovative Medicines Accelerator (IMA)
Current Role at StanfordResearch Scientist at the MCKC
-
Oliv Eidam
Affiliate, Innovative Medicines Accelerator (IMA)
BioDr. Oliv Eidam is an accomplished computational scientist with over a decade of experience in drug discovery within biotech and pharmaceutical industries. As the Director of CADD Consulting GmbH, he leverages expertise in molecular modeling, data science, and cloud computing to drive innovation in drug development. His work has contributed to the successful IPOs of leading biotech firms and the advancement of clinical-stage therapeutics. A passionate leader, Dr. Eidam has built cross-disciplinary teams and authored over 20 high-impact publications and patents. He holds a Ph.D. in Structural Biology from the University of Zurich.
-
Paul S Humphries
Alliance Director, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAlliance Director, Stanford Innovative Medicines Accelerator (IMA)
-
Chaitan Khosla
Wells H. Rauser and Harold M. Petiprin Professor and Professor of Chemistry and, by courtesy, of Biochemistry
Current Research and Scholarly InterestsResearch in this laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health.
For the past two decades, we have studied and engineered enzymatic assembly lines called polyketide synthases that catalyze the biosynthesis of structurally complex and medicinally fascinating antibiotics in bacteria. An example of such an assembly line is found in the erythromycin biosynthetic pathway. Our current focus is on understanding the structure and mechanism of this polyketide synthase. At the same time, we are developing methods to decode the vast and growing number of orphan polyketide assembly lines in the sequence databases.
For more than a decade, we have also investigated the pathogenesis of celiac disease, an autoimmune disorder of the small intestine, with the goal of discovering therapies and related management tools for this widespread but overlooked disease. Ongoing efforts focus on understanding the pivotal role of transglutaminase 2 in triggering the inflammatory response to dietary gluten in the celiac intestine. -
Pallavi Kompella
Lead Research Scientist, Animal Pharmacology, Innovative Medicines Accelerator (IMA)
BioPh.D. Pharmaceutical Sciences, The University of Texas at Austin, Texas
(American Foundation for Pharmaceutical Education Doctoral Fellow)
Fulbright Postdoctoral Scholar, Biomedical Research Institute of Malaga, Spain -
David Solow-Cordero
Associate Director, High-Throughput Screening, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAssociate Director, High-Throughput Screening Knowledge Center, , Sarafan ChEM-H and Innovative Medicine Accelerator (IMA)
This high-throughput screening (HTS) laboratory allows Stanford researchers and others to discover novel modulators of targets that otherwise would not be practical in industry. The center incorporates instrumentation (purchased with NCRR NIH Instrumentation grant numbers S10RR019513, S10RR026338, S10OD025004, and S10OD026899), databases, compound libraries, and personnel whose previous sole domains were in industry.
Among our instrumentation are a fully automated Molecular Devices ImageXpress Micro Confocal High-Content fluorescence microplate imager, with live cell, fluidics and phase contrast options, an Echo 655 Acoustic Dispense, a Thermo integrated HTS robotic system, a Caliper Life Sciences SciClone ALH3000 and an Agilent Bravo microplate liquid handler, and the BMG Clariostarplus, Tecan Infinite M1000 and M1000 PRO and Molecular Devices FlexStation II 384 fluorescence, luminescence and absorbance multimode microplate readers.
We have over 180,000 small molecules for compound screens, 15,000 cDNAs for genomic screens, and whole genome siRNA libraries targeting the human genome (the siARRAY whole human genome siRNA library from Dharmacon, targeting 21,000 human genes) and the mouse genome (Qiagen mouse whole genome siRNA set V1 against 22,124 genes).
The HTSKC main screening lab is located in ChEM-H W008, the cell-based assay development lab is located in CCSR Room 0133-North Wing, between the Transgenic Mouse Facility, and the Stanford Genomics Facility.
